Individuals with ANGPTL3 deficiency exhibit combined hypolipidemia, and an ANGPTL3 inhibitory antibody has been approved for treating homozygous familial hypercholesterolemia (32, 33). Here, ANGPTL3 is linked to familial hypercholesterolemia.